Discover and read the best of Twitter Threads about #BioSimilars
Most recents (3)
Extracts from Syngene Annual Report
CRO,CMO Business
Global CRO Market to grow at CAGR of 7.6% 2019 to 2025 to reach $61 billion
Pharma & biopharmaceutical companies - primary users of CRO services
CRO,CMO Business
Global CRO Market to grow at CAGR of 7.6% 2019 to 2025 to reach $61 billion
Pharma & biopharmaceutical companies - primary users of CRO services
Offlate medical device companies, consumer products,cosmetics, specialty & agrochemicals are also employing the services of CROs
CROs are alts to inhouse R&D, help pharma & biopharma to cut R&D costs manage regulatory requirements, increase speed to market of life saving drugs
CROs are alts to inhouse R&D, help pharma & biopharma to cut R&D costs manage regulatory requirements, increase speed to market of life saving drugs
CRO market
A)Drug discovery - market expected to grow from $3.9bn in 2017 to $6.8bn in 2025 ,CAGR of 7.37%
B)Pre clinical - market expected to grow from $3.5bn in 2017 to $ 6.6bn in 2025 ,CAGR of 8.31%
C) Clinical - market to grow from $25.5bn in 2017 to $41.2bn in 2025
A)Drug discovery - market expected to grow from $3.9bn in 2017 to $6.8bn in 2025 ,CAGR of 7.37%
B)Pre clinical - market expected to grow from $3.5bn in 2017 to $ 6.6bn in 2025 ,CAGR of 8.31%
C) Clinical - market to grow from $25.5bn in 2017 to $41.2bn in 2025
BIOCON
Q4FY20 - Muted growth of 6%,revenue 1644cr ,one time covid impact on Biologics business
Full year ,strong performance, biologics grew 29%,small molecules 18% ,research 10%.
Biologics to recover inQ1 & normalize in Q2
@kiranshaw @Bioconlimited #biosimilars
Q4FY20 - Muted growth of 6%,revenue 1644cr ,one time covid impact on Biologics business
Full year ,strong performance, biologics grew 29%,small molecules 18% ,research 10%.
Biologics to recover inQ1 & normalize in Q2
@kiranshaw @Bioconlimited #biosimilars
Pegfilgrastim,Fulphila commercialized in Australia & Canada
USFDA accepted license application for Bevacizumab
Insulin facility in Malaysia received EIR from USFDA
Indian govt allowed to test Itolizumab in mod to severe Covid ,initial result appear promisin
#COVID19 #biocon
USFDA accepted license application for Bevacizumab
Insulin facility in Malaysia received EIR from USFDA
Indian govt allowed to test Itolizumab in mod to severe Covid ,initial result appear promisin
#COVID19 #biocon
Expect US launch of Insulin Glargine( Semglee) in midCY20 .
Ogivri & Semglee(Insulin Glargine) commercialized in Australia earlier this financial year
Ogivri & Semglee(Insulin Glargine) commercialized in Australia earlier this financial year
Here's my compilation of 13 ideas -- a thread of threads -- of convenient easy ways to speak up & share your voice about US health policy. Geared to rheumatologists but applicable to patients/families & other specialties. You can do a little every day! #Act4Arthritis #ThingADay 
Intro Tweet:
1. Send an email to Congress w/ a few clicks:
